✦ LIBER ✦

Generation, characterization and utilization of anti-human growth hormone 1–43, (hGH1–43), monoclonal antibodies in an ELISA

✍ Scribed by C.C López-Guajardo; L.S Armstrong; L Jordan; N.R Staten; G.G Krivi; A.O Martinez; L.S Haro

Book ID: 114052014
Publisher: Elsevier Science
Year: 1998
Tongue: English
Weight: 116 KB
Volume: 215
Category: Article
ISSN: 0022-1759
DOI: 10.1016/s0022-1759(98)00086-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Production of monoclonal antibodies agai

Production of monoclonal antibodies against human growth hormone releasing hormone and their use in an enzyme-linked immunosorbent assay (ELISA)

✍ Ora Hirsch Pescovitz; Marie C. Gelato; Mary Bundy; D. Lynn Loriaux; George R. Me 📂 Article 📅 1986 🏛 Elsevier Science 🌐 English ⚖ 389 KB

Production of monoclonal antibodies agai

Production of monoclonal antibodies against human growth hormone releasing hormone and their use in an enzyme-linked immunosorbent assay (ELISA)

✍ Ora Hirsch Pescovitz; Marie C. Gelato; Mary Bundy; D. Lynn Loriaux; George R. Me 📂 Article 📅 1987 🏛 Elsevier Science 🌐 English ⚖ 29 KB

Effect of an anti-CD54 (ICAM-1) monoclon

Effect of an anti-CD54 (ICAM-1) monoclonal antibody (UV3) on the growth of human uveal melanoma cells transplanted heterotopically and orthotopically in SCID mice

✍ Shixuan Wang; Elaine J. Coleman; Laurentiu M. Pop; Kimberly J. Brooks; Ellen S. 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 519 KB

## Abstract We have shown that administration of a novel anti‐CD54 monoclonal antibody (UV3) results in long‐term survival of SCID mice bearing human myeloma xenografts. Previous studies have demonstrated a link between the expression of CD54 and the progression of uveal melanoma. Our study assesse

A phase I pharmacokinetic (PK) and seria

A phase I pharmacokinetic (PK) and serial tumor and skin pharmacodynamic (PD) study of weekly, every 2 weeks or every 3 weeks 1-hour (h) infusion EMD72000, an humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients (p) with advanced tumors known to overexpress the EGFR

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 256 KB